DFI Holding Inc.

NEW YORK, NY · Founded 2012 · CIK 0001543229 · Biotech

Antigen-specific immune tolerance platform using allosteric anti-CD40 monoclonal antibody for autoimmune diseases

dfi.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$55M
1 Form D · Apr 2012
174 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$54,944,400
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2116General Folders Inc.—$20K
2117Renasant Bio—$55M
2118PIXIMUNE, INC.——
2119DFI Holding Inc.—$55M
2120Sonoma Biotherapeutics—$265M
2121ARVINAS, INC.—$129M
2122ARBOR EQUITY GROUP FUND I, LP—$500K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Thomas Donohue, Jr.Director
  • John EngsDirector · Executive Officer
  • James FreundExecutive Officer
  • Alan GoldfarbDirector
  • Arthur SilvermanDirector
  • Michael SimanovskyDirector
  • Craig WeinewuthDirector · Executive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.